No Data
Shareholders in Zhejiang Yatai Pharmaceutical (SZSE:002370) Have Lost 53%, as Stock Drops 16% This Past Week
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Zhejiang Yatai Pharmaceutical (002370.SZ): intends to transfer 100% equity of Xingya Pharmaceutical to Zhejiang Zhongqingda.
On March 31, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that on March 31, 2025, the company signed the "Equity Transfer Agreement regarding Shaoxing Xingya Pharmaceutical Co., Ltd." with Zhejiang Zhongqingda Construction Industry Co., Ltd. (hereinafter referred to as "Zhejiang Zhongqingda" or "the transferee"), transferring 100% of the shares of Shaoxing Xingya Pharmaceutical Co., Ltd. (hereinafter referred to as "Xingya Pharmaceutical" or "the symbol company") held by the company to Zhejiang Zhongqingda. As of the date of signing the Equity Transfer Agreement, Xingya Pharmaceutical owes the company a loan of RMB 48.7289 million. Through mutual agreement, this Trade adopts a debt assumption.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Zhejiang Yatai Pharmaceutical (002370.SZ): The injectable form of Ganciclovir has passed the consistency evaluation for generic drugs.
On February 25, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced it recently received the approved notification from the National Medical Products Administration regarding the supplementary application for injectable Ganciclovir. The injectable Ganciclovir has passed the consistency evaluation of generic drug quality and efficacy. Injectable Ganciclovir is suitable for the treatment of life-threatening or sight-threatening cytomegalovirus infections in immunocompromised patients, as well as for the prevention of cytomegalovirus infections in organ transplant patients.
Zhejiang Yatai Pharmaceutical (002370.SZ): Tigecycline for injection has obtained the Pharmaceutical registration certificate.
On February 7, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received the Drug Registration Certificate for Injectable Tigecycline approved and issued by the National Medical Products Administration. Injectable Tigecycline is suitable for patients aged 18 and older for infections caused by specific strains of sensitive bacteria, including: complicated intra-abdominal infections due to sensitive strains of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis (limited to vancomycin-sensitive strains), and Staphylococcus aureus (methicillin-sensitive strains and methicillin-resistant strains.
Some Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) Shareholders Look For Exit As Shares Take 26% Pounding